原发性和转移性肝肿瘤的局部和全身治疗的新联合方法。

IF 1.1 Q4 ONCOLOGY

Clinical Advances in Hematology & Oncology Pub Date : 2023-12-01

Michelle Dai, Bryan-Clement Y Tiu, Millennie Chen, Caitlyn Sing, Vinay Sharma, Juan Pablo Hoyos, Riley Scherr, Wei Ju Lin, Joseph A Breuer, Farshid Dayyani, David Imagawa, Nadine Abi-Jaoudeh

{"title":"原发性和转移性肝肿瘤的局部和全身治疗的新联合方法。","authors":"Michelle Dai, Bryan-Clement Y Tiu, Millennie Chen, Caitlyn Sing, Vinay Sharma, Juan Pablo Hoyos, Riley Scherr, Wei Ju Lin, Joseph A Breuer, Farshid Dayyani, David Imagawa, Nadine Abi-Jaoudeh","doi":"","DOIUrl":null,"url":null,"abstract":"Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways as possible to improve outcomes. Combining several agents has proven to be more effective than the use of monotherapy in the treatment of renal cell carcinoma, hepatocellular carcinoma, and other cancers. Combination therapy can also include locoregional therapies such as ablation and embolization with systemic agents for synergistic effects. This review article discusses the current literature and clinical trials covering these multifactorial combination therapies in primary and metastatic liver tumors.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel combination approaches to locoregional and systemic therapy in the management of primary and metastatic liver tumors.\",\"authors\":\"Michelle Dai, Bryan-Clement Y Tiu, Millennie Chen, Caitlyn Sing, Vinay Sharma, Juan Pablo Hoyos, Riley Scherr, Wei Ju Lin, Joseph A Breuer, Farshid Dayyani, David Imagawa, Nadine Abi-Jaoudeh\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways as possible to improve outcomes. Combining several agents has proven to be more effective than the use of monotherapy in the treatment of renal cell carcinoma, hepatocellular carcinoma, and other cancers. Combination therapy can also include locoregional therapies such as ablation and embolization with systemic agents for synergistic effects. This review article discusses the current literature and clinical trials covering these multifactorial combination therapies in primary and metastatic liver tumors.\",\"PeriodicalId\":51585,\"journal\":{\"name\":\"Clinical Advances in Hematology & Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Advances in Hematology & Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症的发生必须有几种途径和突变。因此，理想的治疗应该针对尽可能多的这些途径，以改善结果。在治疗肾细胞癌、肝细胞癌和其他癌症时，联合使用几种药物已被证明比使用单一疗法更有效。联合治疗也可以包括局部治疗，如消融和栓塞与全身药物协同作用。这篇综述文章讨论了目前的文献和临床试验，涉及这些多因素联合治疗原发性和转移性肝肿瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Novel combination approaches to locoregional and systemic therapy in the management of primary and metastatic liver tumors.

Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways as possible to improve outcomes. Combining several agents has proven to be more effective than the use of monotherapy in the treatment of renal cell carcinoma, hepatocellular carcinoma, and other cancers. Combination therapy can also include locoregional therapies such as ablation and embolization with systemic agents for synergistic effects. This review article discusses the current literature and clinical trials covering these multifactorial combination therapies in primary and metastatic liver tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Advances in Hematology & Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.